Hi Connie, sorry it may be a silly question but has he been exposed to oxaliplatin (eg via FOLFOX) before? This is a common first-line, along with FOLFIRI. Depending on some other factors an anti-VEGF drug such as Avastin (bevacizumab) may also often be considered.
Given he has been on Erbitux I presume he doesn’t have a RAS mutation... do you happen to know his MSS status and/or tumour mutation burden (TMB)? This would be important for potential immunotherapy routes (eg Keytruda/Opdivo).
The folk at CoH should be all over this stuff though anyway. Best wishes to you both.
Male 37 years; Melbourne, Australia
10/2018 Dx: 3.5 cm rectal adenocarcinoma, 10 cm from verge. Well/mod diff (G1-2), T3bN1bM1a.
3 enlarged local lymph nodes and 4 liver lesions.
MSS, MMR-proficient, mutated in NRAS (G13R).
CEA: Oct-18 = 12; Nov-18 = 14, Mar-19 = 2.4
11/18 - 6 cycles neoadjuvant FOLFOX
12/18 - DVT, started clexane
3/19 - Liver resection, R0
4-5/19 - Long-course pelvic chemoradiation (45 Gy w/ Xeloda)
07/19 - Planned restaging scans and ULAR w temp ileo